<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310804</url>
  </required_header>
  <id_info>
    <org_study_id>V58P9</org_study_id>
    <secondary_id>EUDRACT: 2005-002257-47</secondary_id>
    <nct_id>NCT00310804</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (&gt;=18 to &lt;=60)</brief_title>
  <official_title>A Phase III, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of Three Lots of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Or of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs, in Healthy Adult Subjects Aged &gt;=18 to &lt;=60</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to evaluate safety, tolerability and immunogenicity of three lots of
      Chiron's cell-derived subunit influenza vaccine in healthy adult subjects as compared to a
      conventional egg-derived control vaccine licensed in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult Subjects</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>The haemagglutinin Inhibition (HI) antibody titer response following
one dose of cTIV for each of the three lots separately and
one dose of cTIV (combined) compared to TIV is reported as Geometric mean titers (GMTs).
The HI GMTs were evaluated using egg-derived antigen assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratios After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult Subjects</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>Immunogenicity was assessed in terms of Geometric Mean Ratio (GMR) following
one dose of cTIV for each of the three vaccine lots separately and
for one dose of cTIV (combined) compared to TIV, according to the CHMP criterion.
The European licensure (CHMP) criterion is met if the mean geometric increase (GMR, day 22/day 1) in HI antibody titer is &gt;2.5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With HI Titers ≥40</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>Immunogenicity was assessed in terms of percentage of adult subjects achieving HI titers ≥40, after
one dose of cTIV for each of the three vaccine lots separately and
for one dose of cTIV (combined) compared to TIV, according to the CHMP criterion.
European Licensure (CHMP) criterion is met if the percentage of subjects achieving HI titers ≥40 is &gt;70%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Seroconversion or Significant Increase in HI Antibody Titers After One Dose of Either Cell-derived or Egg-derived Subunit Trivalent Influenza Vaccine</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>Immunogenicity was assessed in terms of percentage of adult subjects showing seroconversion or significant increase in HI antibody titers after
one dose of cTIV for each of the three vaccine lots separately and
one dose of cTIV (combined) compared to TIV, according to the CHMP criterion.
European Licensure (CHMP) criterion is met if the percentage of subjects achieving seroconversion or significant increase is &gt;40%.
As per European Licensure (CHMP) criterion seroconversion is defined as percentage of subjects with a prevaccination HI titer &lt;10 to a postvaccination titer ≥40; whereas, significant increase is defined as HI titer ≥10 prevaccination and ≥4-fold Hi titer increase post-vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine.</measure>
    <time_frame>Day 1 to Day 7 postvaccination</time_frame>
    <description>To assess the safety and tolerability in terms of number of subjects reporting solicited adverse events following one injection of
one dose of cTIV for each of the three vaccine lots separately and
for one dose of cTIV (combined) compared to TIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Data of Subjects Upto Six Months After One Dose of Cell Culture Derived or Egg-derived Influenza Vaccine</measure>
    <time_frame>Day 1 - Day 181 postvaccination</time_frame>
    <description>Additional safety data from day 1 through day 181 after one dose of cTIV (combined) or TIV in terms of serious adverse events (SAEs), adverse events (AEs) necessitating a physician's visit and/or resulting in premature subject's withdrawal from study is reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>cTIV_lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cTIV_lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cTIV_lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)</intervention_name>
    <description>One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1</description>
    <arm_group_label>cTIV_lot 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)</intervention_name>
    <description>One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2</description>
    <arm_group_label>cTIV_lot 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)</intervention_name>
    <description>One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3</description>
    <arm_group_label>cTIV_lot 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)</intervention_name>
    <description>One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).</description>
    <arm_group_label>TIV group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to &lt;61 years of age

          2. mentally competent to understand the nature, the scope and the consequences of the
             study

          3. able and willing to give written informed consent prior to study entry

          4. in good health as determined by:

               1. medical history,

               2. physical examination,

               3. clinical judgment of the Investigator.

        Exclusion Criteria:

          1. unwilling or unable to give written informed consent to participate in the study

          2. participation in another clinical trial of an investigational agent within 90 days
             prior to Visit 1 and throughout the entire study

          3. currently experiencing an acute infectious disease

          4. any serious disease, such as, for example:

               1. cancer,

               2. autoimmune disease (including rheumatoid arthritis),

               3. advanced arteriosclerotic disease or complicated diabetes mellitus,

               4. chronic obstructive pulmonary disease (COPD) requiring oxygen therapy,

               5. acute or progressive hepatic disease,

               6. acute or progressive renal disease,

               7. congestive heart failure

          5. surgery planned during the study period

          6. bleeding diathesis

          7. history of hypersensitivity to any component of the study medication or chemically
             related substances

          8. history of any anaphylaxis, serious vaccine reactions, or allergy to any of the
             vaccine component

          9. known or suspected impairment/alteration of immune function, for example resulting
             from:

               1. receipt of immunosuppressive therapy (any corticosteroid therapy or cancer
                  chemotherapy),

               2. receipt of immunostimulants,

               3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivates within 3 months prior to Visit 1 or planned during the full length of
                  the study,

               4. high risk for developing an immunocompromising disease

         10. history of drug or alcohol abuse

         11. laboratory-confirmed influenza disease within 6 months prior to Visit 1

         12. receipt of influenza vaccine within 6 months prior to Visit 1

         13. receipt of another vaccine within 60 days prior to Visit 1, or planned vaccination
             within 3 weeks following study vaccination

         14. any acute respiratory disease or infections requiring systemic antibiotic or antiviral
             therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) or
             experienced fever (i.e., axillary temperature ≥ 38 degree C) within 5 days prior to
             Visit 1

         15. if female, pregnant or breastfeeding

         16. if female, refusal to use a reliable contraceptive method during the three weeks
             following vaccination

         17. planned relocation abroad during the study period

         18. any condition that, in the opinion of the Investigator, might interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines &amp; Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2nd Department of Internal Diseases, Panevezys Hospital,</name>
      <address>
        <city>Panevezys</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Infectious Diseases and Microbiology of Vilnius University</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <results_reference>
    <citation>Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine. 2009 Oct 9;27(43):6022-9. doi: 10.1016/j.vaccine.2009.07.083. Epub 2009 Aug 8.</citation>
    <PMID>19666152</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2006</study_first_submitted>
  <study_first_submitted_qc>April 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2006</study_first_posted>
  <results_first_submitted>December 11, 2012</results_first_submitted>
  <results_first_submitted_qc>December 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2013</results_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Flu</keyword>
  <keyword>Cell-Derived</keyword>
  <keyword>Egg-Derived</keyword>
  <keyword>Healthy Adults</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from a single site in Lithuania.</recruitment_details>
      <pre_assignment_details>All participants enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>cTIV (Combined)</title>
          <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot1, Lot2 or Lot3).</description>
        </group>
        <group group_id="P2">
          <title>TIV Group</title>
          <description>Subjects in this group received one dose of Egg derived Trivalent Subunit Influenza Vaccine (TIV).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1029"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1024"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>cTIV (Combined)</title>
          <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot1, Lot2 or Lot3).</description>
        </group>
        <group group_id="B2">
          <title>TIV Group</title>
          <description>Subjects in this group received one dose of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="600"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="700"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="11.1"/>
                    <measurement group_id="B2" value="26.9" spread="11.5"/>
                    <measurement group_id="B3" value="27.2" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="321"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="279"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="600"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult Subjects</title>
        <description>The haemagglutinin Inhibition (HI) antibody titer response following
one dose of cTIV for each of the three lots separately and
one dose of cTIV (combined) compared to TIV is reported as Geometric mean titers (GMTs).
The HI GMTs were evaluated using egg-derived antigen assay.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>This analysis was done on per protocol (PP) population defined as all subjects who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV_lot1</title>
            <description>Subjects in this group received one dose of Cell-Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>cTIV_lot 2</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2</description>
          </group>
          <group group_id="O3">
            <title>cTIV_lot3</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3.</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Combined)</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot1, Lot2 or Lot3).</description>
          </group>
          <group group_id="O5">
            <title>TIV Group</title>
            <description>Subjects in this group received one dose of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult Subjects</title>
          <description>The haemagglutinin Inhibition (HI) antibody titer response following
one dose of cTIV for each of the three lots separately and
one dose of cTIV (combined) compared to TIV is reported as Geometric mean titers (GMTs).
The HI GMTs were evaluated using egg-derived antigen assay.</description>
          <population>This analysis was done on per protocol (PP) population defined as all subjects who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol deviation.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="589"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H3N2 strain (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="11" upper_limit="14"/>
                    <measurement group_id="O2" value="15" lower_limit="13" upper_limit="17"/>
                    <measurement group_id="O3" value="16" lower_limit="14" upper_limit="19"/>
                    <measurement group_id="O4" value="14" lower_limit="13" upper_limit="16"/>
                    <measurement group_id="O5" value="15" lower_limit="12" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain (day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" lower_limit="147" upper_limit="207"/>
                    <measurement group_id="O2" value="171" lower_limit="144" upper_limit="203"/>
                    <measurement group_id="O3" value="158" lower_limit="133" upper_limit="188"/>
                    <measurement group_id="O4" value="168" lower_limit="152" upper_limit="185"/>
                    <measurement group_id="O5" value="186" lower_limit="146" upper_limit="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 strain (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="17" upper_limit="24"/>
                    <measurement group_id="O2" value="20" lower_limit="17" upper_limit="25"/>
                    <measurement group_id="O3" value="21" lower_limit="17" upper_limit="25"/>
                    <measurement group_id="O4" value="20" lower_limit="18" upper_limit="22"/>
                    <measurement group_id="O5" value="22" lower_limit="18" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 strain (day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390" lower_limit="326" upper_limit="466"/>
                    <measurement group_id="O2" value="364" lower_limit="303" upper_limit="436"/>
                    <measurement group_id="O3" value="366" lower_limit="306" upper_limit="437"/>
                    <measurement group_id="O4" value="373" lower_limit="335" upper_limit="415"/>
                    <measurement group_id="O5" value="329" lower_limit="253" upper_limit="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O2" value="17" lower_limit="14" upper_limit="19"/>
                    <measurement group_id="O3" value="14" lower_limit="12" upper_limit="16"/>
                    <measurement group_id="O4" value="14" lower_limit="13" upper_limit="16"/>
                    <measurement group_id="O5" value="16" lower_limit="13" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" lower_limit="113" upper_limit="151"/>
                    <measurement group_id="O2" value="157" lower_limit="136" upper_limit="182"/>
                    <measurement group_id="O3" value="128" lower_limit="111" upper_limit="148"/>
                    <measurement group_id="O4" value="138" lower_limit="126" upper_limit="151"/>
                    <measurement group_id="O5" value="124" lower_limit="99" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratios After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult Subjects</title>
        <description>Immunogenicity was assessed in terms of Geometric Mean Ratio (GMR) following
one dose of cTIV for each of the three vaccine lots separately and
for one dose of cTIV (combined) compared to TIV, according to the CHMP criterion.
The European licensure (CHMP) criterion is met if the mean geometric increase (GMR, day 22/day 1) in HI antibody titer is &gt;2.5.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>The analysis was performed as PP dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV_lot1</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>cTIV_lot 2</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2.</description>
          </group>
          <group group_id="O3">
            <title>cTIV_lot3</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3.</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Combined)</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot1, Lot2 or Lot3).</description>
          </group>
          <group group_id="O5">
            <title>TIV Group</title>
            <description>Subjects in this group received one dose of Egg-Derived Trivalent Subunit Influenza Vaccine(TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult Subjects</title>
          <description>Immunogenicity was assessed in terms of Geometric Mean Ratio (GMR) following
one dose of cTIV for each of the three vaccine lots separately and
for one dose of cTIV (combined) compared to TIV, according to the CHMP criterion.
The European licensure (CHMP) criterion is met if the mean geometric increase (GMR, day 22/day 1) in HI antibody titer is &gt;2.5.</description>
          <population>The analysis was performed as PP dataset.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="589"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain (Day22/Day1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O2" value="18" lower_limit="14" upper_limit="22"/>
                    <measurement group_id="O3" value="18" lower_limit="14" upper_limit="22"/>
                    <measurement group_id="O4" value="18" lower_limit="16" upper_limit="21"/>
                    <measurement group_id="O5" value="15" lower_limit="11" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain (Day22/Day1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="12" upper_limit="17"/>
                    <measurement group_id="O2" value="11" lower_limit="9.55" upper_limit="14"/>
                    <measurement group_id="O3" value="9.92" lower_limit="8.28" upper_limit="12"/>
                    <measurement group_id="O4" value="12" lower_limit="11" upper_limit="13"/>
                    <measurement group_id="O5" value="12" lower_limit="9.57" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (Day22/Day1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8.59" upper_limit="12"/>
                    <measurement group_id="O2" value="9.42" lower_limit="7.97" upper_limit="11"/>
                    <measurement group_id="O3" value="9.37" lower_limit="7.94" upper_limit="11"/>
                    <measurement group_id="O4" value="9.63" lower_limit="8.71" upper_limit="11"/>
                    <measurement group_id="O5" value="7.53" lower_limit="5.88" upper_limit="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With HI Titers ≥40</title>
        <description>Immunogenicity was assessed in terms of percentage of adult subjects achieving HI titers ≥40, after
one dose of cTIV for each of the three vaccine lots separately and
for one dose of cTIV (combined) compared to TIV, according to the CHMP criterion.
European Licensure (CHMP) criterion is met if the percentage of subjects achieving HI titers ≥40 is &gt;70%.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>This analysis was done on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV_lot 1</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>cTIV_lot 2</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2.</description>
          </group>
          <group group_id="O3">
            <title>cTIV_lot 3</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3.</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Combined)</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot1, Lot2 or Lot3).</description>
          </group>
          <group group_id="O5">
            <title>TIV Group</title>
            <description>Subjects in this group received one dose of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With HI Titers ≥40</title>
          <description>Immunogenicity was assessed in terms of percentage of adult subjects achieving HI titers ≥40, after
one dose of cTIV for each of the three vaccine lots separately and
for one dose of cTIV (combined) compared to TIV, according to the CHMP criterion.
European Licensure (CHMP) criterion is met if the percentage of subjects achieving HI titers ≥40 is &gt;70%.</description>
          <population>This analysis was done on PP population.</population>
          <units>Percentages</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="589"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="29" upper_limit="43"/>
                    <measurement group_id="O2" value="38" lower_limit="31" upper_limit="46"/>
                    <measurement group_id="O3" value="34" lower_limit="27" upper_limit="41"/>
                    <measurement group_id="O4" value="36" lower_limit="32" upper_limit="40"/>
                    <measurement group_id="O5" value="38" lower_limit="28" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 strain (day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O3" value="94" lower_limit="90" upper_limit="97"/>
                    <measurement group_id="O4" value="96" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O5" value="97" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O2" value="31" lower_limit="24" upper_limit="38"/>
                    <measurement group_id="O3" value="28" lower_limit="22" upper_limit="35"/>
                    <measurement group_id="O4" value="26" lower_limit="22" upper_limit="30"/>
                    <measurement group_id="O5" value="28" lower_limit="19" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain (day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="88" upper_limit="96"/>
                    <measurement group_id="O2" value="93" lower_limit="88" upper_limit="96"/>
                    <measurement group_id="O3" value="91" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O4" value="92" lower_limit="90" upper_limit="94"/>
                    <measurement group_id="O5" value="97" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="19" upper_limit="32"/>
                    <measurement group_id="O2" value="31" lower_limit="25" upper_limit="38"/>
                    <measurement group_id="O3" value="25" lower_limit="19" upper_limit="31"/>
                    <measurement group_id="O4" value="27" lower_limit="23" upper_limit="31"/>
                    <measurement group_id="O5" value="31" lower_limit="22" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="88" upper_limit="96"/>
                    <measurement group_id="O2" value="94" lower_limit="90" upper_limit="97"/>
                    <measurement group_id="O3" value="93" lower_limit="89" upper_limit="96"/>
                    <measurement group_id="O4" value="93" lower_limit="91" upper_limit="95"/>
                    <measurement group_id="O5" value="93" lower_limit="86" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Seroconversion or Significant Increase in HI Antibody Titers After One Dose of Either Cell-derived or Egg-derived Subunit Trivalent Influenza Vaccine</title>
        <description>Immunogenicity was assessed in terms of percentage of adult subjects showing seroconversion or significant increase in HI antibody titers after
one dose of cTIV for each of the three vaccine lots separately and
one dose of cTIV (combined) compared to TIV, according to the CHMP criterion.
European Licensure (CHMP) criterion is met if the percentage of subjects achieving seroconversion or significant increase is &gt;40%.
As per European Licensure (CHMP) criterion seroconversion is defined as percentage of subjects with a prevaccination HI titer &lt;10 to a postvaccination titer ≥40; whereas, significant increase is defined as HI titer ≥10 prevaccination and ≥4-fold Hi titer increase post-vaccination.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>This analysis was done on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV_lot1</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>cTIV_lot 2</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2.</description>
          </group>
          <group group_id="O3">
            <title>cTIV_lot3</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from lot 3.</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Combined)</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot1, Lot2 or Lot3).</description>
          </group>
          <group group_id="O5">
            <title>TIV Group</title>
            <description>Subjects in this group received one dose of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroconversion or Significant Increase in HI Antibody Titers After One Dose of Either Cell-derived or Egg-derived Subunit Trivalent Influenza Vaccine</title>
          <description>Immunogenicity was assessed in terms of percentage of adult subjects showing seroconversion or significant increase in HI antibody titers after
one dose of cTIV for each of the three vaccine lots separately and
one dose of cTIV (combined) compared to TIV, according to the CHMP criterion.
European Licensure (CHMP) criterion is met if the percentage of subjects achieving seroconversion or significant increase is &gt;40%.
As per European Licensure (CHMP) criterion seroconversion is defined as percentage of subjects with a prevaccination HI titer &lt;10 to a postvaccination titer ≥40; whereas, significant increase is defined as HI titer ≥10 prevaccination and ≥4-fold Hi titer increase post-vaccination.</description>
          <population>This analysis was done on PP population.</population>
          <units>Percentages</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="589"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="74" upper_limit="86"/>
                    <measurement group_id="O2" value="81" lower_limit="75" upper_limit="86"/>
                    <measurement group_id="O3" value="82" lower_limit="76" upper_limit="87"/>
                    <measurement group_id="O4" value="81" lower_limit="78" upper_limit="84"/>
                    <measurement group_id="O5" value="76" lower_limit="66" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="78" upper_limit="89"/>
                    <measurement group_id="O2" value="79" lower_limit="72" upper_limit="84"/>
                    <measurement group_id="O3" value="78" lower_limit="71" upper_limit="83"/>
                    <measurement group_id="O4" value="80" lower_limit="77" upper_limit="83"/>
                    <measurement group_id="O5" value="88" lower_limit="80" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="72" upper_limit="84"/>
                    <measurement group_id="O2" value="81" lower_limit="75" upper_limit="87"/>
                    <measurement group_id="O3" value="80" lower_limit="74" upper_limit="85"/>
                    <measurement group_id="O4" value="80" lower_limit="77" upper_limit="83"/>
                    <measurement group_id="O5" value="70" lower_limit="60" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine.</title>
        <description>To assess the safety and tolerability in terms of number of subjects reporting solicited adverse events following one injection of
one dose of cTIV for each of the three vaccine lots separately and
for one dose of cTIV (combined) compared to TIV.</description>
        <time_frame>Day 1 to Day 7 postvaccination</time_frame>
        <population>Analysis was done on safety dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV_lot1</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1.</description>
          </group>
          <group group_id="O2">
            <title>cTIV_lot2</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2.</description>
          </group>
          <group group_id="O3">
            <title>cTIV_lot3</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3.</description>
          </group>
          <group group_id="O4">
            <title>cTIV (Combined)</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot1, Lot2 or Lot3).</description>
          </group>
          <group group_id="O5">
            <title>TIV Group</title>
            <description>Subjects in this group received one dose of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine.</title>
          <description>To assess the safety and tolerability in terms of number of subjects reporting solicited adverse events following one injection of
one dose of cTIV for each of the three vaccine lots separately and
for one dose of cTIV (combined) compared to TIV.</description>
          <population>Analysis was done on safety dataset.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="599"/>
                <count group_id="O5" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="134"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="170"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="91"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;=38C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home due to reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic Antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Data of Subjects Upto Six Months After One Dose of Cell Culture Derived or Egg-derived Influenza Vaccine</title>
        <description>Additional safety data from day 1 through day 181 after one dose of cTIV (combined) or TIV in terms of serious adverse events (SAEs), adverse events (AEs) necessitating a physician's visit and/or resulting in premature subject's withdrawal from study is reported.</description>
        <time_frame>Day 1 - Day 181 postvaccination</time_frame>
        <population>This analysis was done on safety dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Combined) Day 1 to Day 22</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot 1, Lot2 or Lot3).</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Combined) Day 23 to Day 181</title>
            <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot1, Lot2 or Lot3).</description>
          </group>
          <group group_id="O3">
            <title>TIV Group Day 1 to Day 22</title>
            <description>Subjects in this group received one dose of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).</description>
          </group>
          <group group_id="O4">
            <title>TIV Group Day 23 to Day 181</title>
            <description>Subjects in this group received one dose of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Data of Subjects Upto Six Months After One Dose of Cell Culture Derived or Egg-derived Influenza Vaccine</title>
          <description>Additional safety data from day 1 through day 181 after one dose of cTIV (combined) or TIV in terms of serious adverse events (SAEs), adverse events (AEs) necessitating a physician's visit and/or resulting in premature subject's withdrawal from study is reported.</description>
          <population>This analysis was done on safety dataset.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="571"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through out the study period</time_frame>
      <desc>Post-injection solicited adverse events were collected from Day1-7. Other AE's and SAEs were collected through out the study period (Day 1 to 6 months).
In cTIV(Combined group),599/600 subjects were included in safety dataset as one subject did not receive the vaccination and withdrew on day 1.</desc>
      <group_list>
        <group group_id="E1">
          <title>cTIV (Combined)</title>
          <description>Subjects in this group received one dose of Cell Derived Trivalent Subunit Influenza Vaccine from one of three vaccine Lots (Lot1, Lot2 or Lot3).</description>
        </group>
        <group group_id="E2">
          <title>TIV Group</title>
          <description>Subjects in this group received one dose of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury Asphyxiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Schizoid Personality Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Essential Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="599"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because of potential issues related to Good Clinical Practice (GCP), data from one of the sites were not used in the analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

